Evaluation of accordance of antibiotics package size with recommended treatment duration of guidelines for sore throat and urinary tract infections.
Antibiotic resistance
Prescribing guideline
Sore throat
Urinary tract infections
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
12
2018
accepted:
04
02
2019
entrez:
23
2
2019
pubmed:
23
2
2019
medline:
3
3
2020
Statut:
epublish
Résumé
The aim of this study was to investigate whether marketed antibiotics package sizes are in accordance with treatment durations recommended in guidelines for prescribing antibiotics in sore throat and urinary tract infections. National drug database was searched with limitation to Antibacterials for systemic use. Formulations which did not have pre-specified dosage unit by the manufacturer were excluded (e.g. powders for oral solutions). The final list contained 94 drugs with 23 different active substances. This list was then cross-referenced with selected antimicrobial prescribing guidelines provided by Intersectoral Society for Antibiotic Resistance Control (ISKRA), National Institute for Health and Care Excellence (NICE) and The Infectious Diseases Society of America (IDSA). Seven packages matched ISKRA guidelines on sore throat while 16 were mismatched. Considering drug packages under reimbursement, 3 matched ISKRA guidelines and 8 were mismatched. Only 3 packages matched IDSA guidelines for comparable indications, and 18 were mismatched. When considering NICE guidelines there were 5 mismatched and only one package that was in accordance with the guidelines. ISKRA guidelines for urinary tract infections matched 23 packages and mismatched 58 packages. IDSA guidelines for urinary tract infections matched one package and were mismatched in 15 cases. One of the causes of leftover antibiotics is poor accordance of antibiotic package size with treatment recommendation duration. This should be identified as a potential target for reduction of excess antibiotics in the community. Measures that promote patient adherence to therapy and patient education should be considered essential to manage proper handling of leftover antibiotics.
Sections du résumé
Background
The aim of this study was to investigate whether marketed antibiotics package sizes are in accordance with treatment durations recommended in guidelines for prescribing antibiotics in sore throat and urinary tract infections.
Methods
National drug database was searched with limitation to Antibacterials for systemic use. Formulations which did not have pre-specified dosage unit by the manufacturer were excluded (e.g. powders for oral solutions). The final list contained 94 drugs with 23 different active substances. This list was then cross-referenced with selected antimicrobial prescribing guidelines provided by Intersectoral Society for Antibiotic Resistance Control (ISKRA), National Institute for Health and Care Excellence (NICE) and The Infectious Diseases Society of America (IDSA).
Results
Seven packages matched ISKRA guidelines on sore throat while 16 were mismatched. Considering drug packages under reimbursement, 3 matched ISKRA guidelines and 8 were mismatched. Only 3 packages matched IDSA guidelines for comparable indications, and 18 were mismatched. When considering NICE guidelines there were 5 mismatched and only one package that was in accordance with the guidelines. ISKRA guidelines for urinary tract infections matched 23 packages and mismatched 58 packages. IDSA guidelines for urinary tract infections matched one package and were mismatched in 15 cases.
Conclusions
One of the causes of leftover antibiotics is poor accordance of antibiotic package size with treatment recommendation duration. This should be identified as a potential target for reduction of excess antibiotics in the community. Measures that promote patient adherence to therapy and patient education should be considered essential to manage proper handling of leftover antibiotics.
Identifiants
pubmed: 30792852
doi: 10.1186/s13756-019-0495-5
pii: 495
pmc: PMC6371554
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Déclaration de conflit d'intérêts
Not applicable.Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Lancet Infect Dis. 2014 Aug;14(8):742-750
pubmed: 25022435
Crit Rev Food Sci Nutr. 2017 Sep 2;57(13):2857-2876
pubmed: 26464037
Environ Sci Technol. 2015 Jun 2;49(11):6772-82
pubmed: 25961663
Front Microbiol. 2018 Jan 17;8:2603
pubmed: 29387043
BMC Public Health. 2017 Oct 10;17(1):799
pubmed: 29017473
J Antimicrob Chemother. 2007 Aug;60 Suppl 1:i43-47
pubmed: 17656380
Lijec Vjesn. 2009 May-Jun;131(5-6):105-18
pubmed: 19642528
J Am Pharm Assoc (Wash). 2002 Jan-Feb;42(1):12-5
pubmed: 11833504
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):19-26
pubmed: 29490060
BMC Infect Dis. 2014 Jan 09;14:13
pubmed: 24405683
J Antimicrob Chemother. 2002 Jun;49(6):897-903
pubmed: 12039881
Can Fam Physician. 2017 Dec;63(12):e526-e535
pubmed: 29237649
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):ii36-ii43
pubmed: 29490058
Pharmacotherapy. 2017 Jan;37(1):71-84
pubmed: 27859453
BMJ. 2013 Mar 11;346:f1493
pubmed: 23479660
World J Emerg Surg. 2018 Jun 28;13:27
pubmed: 29988647
BMJ. 2017 Jul 26;358:j3418
pubmed: 28747365
Euro Surveill. 2015 May 28;20(21):
pubmed: 26062562
J Antimicrob Chemother. 2018 Jun 1;73(suppl_6):vi30-vi39
pubmed: 29878221
Aust N Z J Public Health. 2015 Dec;39(6):569-72
pubmed: 26122469
Basic Clin Pharmacol Toxicol. 2018 Mar;122(3):317-321
pubmed: 28889650
JAMA. 2013 Jun 12;309(22):2345-52
pubmed: 23757082
BMC Med. 2014 Jun 11;12:96
pubmed: 24916809
Infect Control Hosp Epidemiol. 2018 Mar;39(3):316-322
pubmed: 29402339
Lijec Vjesn. 2009 Jul-Aug;131(7-8):181-91
pubmed: 19769278
Int J Clin Pharm. 2014 Jun;36(3):556-63
pubmed: 24687486
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654
JAMA Intern Med. 2016 Sep 1;176(9):1254-5
pubmed: 27455385
Environ Int. 2018 Nov;120:421-430
pubmed: 30125859
J Antimicrob Chemother. 2007 Aug;60 Suppl 1:i63-8
pubmed: 17656386
Clin Infect Dis. 2012 Nov 15;55(10):e86-102
pubmed: 22965026
JAMA. 2016 Sep 20;316(11):1193-1204
pubmed: 27654605
PLoS One. 2017 Sep 19;12(9):e0184420
pubmed: 28926636
BMJ. 2017 Sep 22;358:j4170
pubmed: 28939553